Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders
US8105632B2 · kind B2 · utility
6Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 7, 2005 |
| Grant date | Jan 31, 2012 |
| Priority date | — |
| Expiry date | Aug 18, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P41/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions comprising membrane-derived and synthetic microparticles that induce platelet aggregation and are useful for treating bleeding disorders, particularly those involving platelet dysfunction. Microparticles include endothelial derived microparticles (EMP), platelet derived microparticles (PMP), erythrocyte derived microparticles (RMP), and synthetic microparticles (SMP), and are used to treat disorders such as thrombocytopenia caused by chemotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.